{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:50:36Z","timestamp":1790740236700,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Council"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s10096-021-04201-w","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T03:02:25Z","timestamp":1614394945000},"page":"1521-1528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9457-8262","authenticated-orcid":false,"given":"Indy","family":"Sandaradura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J. E.","family":"Marriott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard O.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross L. G.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie L.","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie E.","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,27]]},"reference":[{"key":"4201_CR1","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.3201\/eid1210.060389","volume":"12","author":"S Chen","year":"2006","unstructured":"Chen S, Slavin M, Nguyen Q et al (2006) Active surveillance for candidemia, Australia. Emerg Infect Dis 12:1508\u20131516","journal-title":"Emerg Infect Dis"},{"key":"4201_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1473-3099(03)00801-6","volume":"3","author":"P Eggimann","year":"2003","unstructured":"Eggimann P, Garbino J, Pittet D (2003) Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 3:685\u2013702","journal-title":"Lancet Infect Dis"},{"key":"4201_CR3","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1097\/CCM.0000000000000221","volume":"42","author":"M Puig-Asensio","year":"2014","unstructured":"Puig-Asensio M, Pem\u00e1n J, Zaragoza R et al (2014) Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Crit Care Med 42:1423\u20131432","journal-title":"Crit Care Med"},{"key":"4201_CR4","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1097\/CCM.0b013e31818b3477","volume":"36","author":"AJ Labelle","year":"2008","unstructured":"Labelle AJ, Micek ST, Roubinian N, Kollef MH (2008) Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 36:2967\u20132972","journal-title":"Crit Care Med"},{"key":"4201_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1471-2334-10-150","volume":"10","author":"MD Zilberberg","year":"2010","unstructured":"Zilberberg MD, Kollef MH, Arnold H et al (2010) Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis 10:150","journal-title":"BMC Infect Dis"},{"key":"4201_CR6","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J et al (2014) Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14:498\u2013509","journal-title":"Lancet Infect Dis"},{"key":"4201_CR7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1086\/596757","volume":"48","author":"PG Pappas","year":"2009","unstructured":"Pappas PG, Kauffman CA, Andes D et al (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503\u2013535","journal-title":"Clin Infect Dis"},{"key":"4201_CR8","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/jac\/dki473","volume":"57","author":"C Charlier","year":"2006","unstructured":"Charlier C, Hart E, Lefort A et al (2006) Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 57:384\u2013410","journal-title":"J Antimicrob Chemother"},{"key":"4201_CR9","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1128\/AAC.39.5.1154","volume":"39","author":"F Thaler","year":"1995","unstructured":"Thaler F, Bernard B, Tod M et al (1995) Fluconazole penetration in cerebral parenchyma in humans at steady state. Antimicrob Agents Chemother 39:1154\u20131156","journal-title":"Antimicrob Agents Chemother"},{"key":"4201_CR10","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1128\/AAC.00296-07","volume":"51","author":"JL Rodr\u00edguez-Tudela","year":"2007","unstructured":"Rodr\u00edguez-Tudela JL, Almirante B, Rodr\u00edguez-Pardo D et al (2007) Correlation of the MIC and dose\/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother 51:3599\u20133604","journal-title":"Antimicrob Agents Chemother"},{"key":"4201_CR11","unstructured":"Anon. DIFLUCAN. Product Information 2014. Available at: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=575. Accessed 5 Jan 2017"},{"key":"4201_CR12","doi-asserted-by":"crossref","unstructured":"Pappas PG, Kauffman CA, Andes DR et al (2016) Clinical practice guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62:e1\u2013e50","DOI":"10.1093\/cid\/civ933"},{"key":"4201_CR13","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1128\/AAC.01088-16","volume":"60","author":"AS Alobaid","year":"2016","unstructured":"Alobaid AS, Wallis SC, Jarrett P et al (2016) Effect of obesity on the population pharmacokinetics of fluconazole in critically ill patients. Antimicrob Agents Chemother 60:6550\u20136557","journal-title":"Antimicrob Agents Chemother"},{"key":"4201_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1046\/j.1439-0507.1999.00269.x","volume":"42","author":"L Pittrow","year":"1999","unstructured":"Pittrow L, Penk A (1999) Dosage adjustment of fluconazole during continuous renal replacement therapy (CAVH, CVVH, CAVHD, CVVHD). Mycoses 42:17\u201319","journal-title":"Mycoses"},{"key":"4201_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s002280000216","volume":"56","author":"E Muhl","year":"2000","unstructured":"Muhl E, Martens T, Iven H, Rob P, Bruch HP (2000) Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Eur J Clin Pharmacol 56:671\u2013678","journal-title":"Eur J Clin Pharmacol"},{"key":"4201_CR16","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1007\/s00134-003-1980-z","volume":"29","author":"K Yagasaki","year":"2003","unstructured":"Yagasaki K, Gando S, Matsuda N et al (2003) Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration. Intensive Care Med 29:1844\u20131848","journal-title":"Intensive Care Med"},{"key":"4201_CR17","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/ndt\/gfi284","volume":"21","author":"R Bergner","year":"2006","unstructured":"Bergner R, Hoffmann M, Riedel K-D et al (2006) Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg. Nephrol Dial Transplant 21:1019\u20131023","journal-title":"Nephrol Dial Transplant"},{"key":"4201_CR18","doi-asserted-by":"publisher","unstructured":"Muilwijk EW, de Lange DW, Schouten JA et al (2020) Suboptimal dosing of fluconazole in critically ill patients: time to rethink dosing. Antimicrob Agents Chemother 64. https:\/\/doi.org\/10.1128\/AAC.00984-20","DOI":"10.1128\/AAC.00984-20"},{"key":"4201_CR19","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1093\/cid\/cis021","volume":"54","author":"DR Andes","year":"2012","unstructured":"Andes DR, Safdar N, Baddley JW et al (2012) Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 54:1110\u20131122","journal-title":"Clin Infect Dis"},{"key":"4201_CR20","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1128\/AAC.00116-08","volume":"52","author":"JW Baddley","year":"2008","unstructured":"Baddley JW, Patel M, Bhavnani SM, Moser SA, Andes DR (2008) Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 52:3022\u20133028","journal-title":"Antimicrob Agents Chemother"},{"key":"4201_CR21","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1093\/jac\/dku313","volume":"69","author":"EW Muilwijk","year":"2014","unstructured":"Muilwijk EW, Schouten JA, van Leeuwen HJ et al (2014) Pharmacokinetics of caspofungin in ICU patients. J Antimicrob Chemother 69:3294\u20133299","journal-title":"J Antimicrob Chemother"},{"key":"4201_CR22","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1128\/AAC.00424-11","volume":"55","author":"K Patel","year":"2011","unstructured":"Patel K, Roberts JA, Lipman J, Tett SE, Deldot ME, Kirkpatrick CM (2011) Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets. Antimicrob Agents Chemother 55:5868\u20135873","journal-title":"Antimicrob Agents Chemother"},{"key":"4201_CR23","doi-asserted-by":"publisher","unstructured":"Alobaid AS, Wallis SC, Jarrett P et al (2017) Population pharmacokinetics of piperacillin in nonobese, obese, and morbidly obese critically ill patients. Antimicrob Agents Chemother 61. https:\/\/doi.org\/10.1128\/AAC.01276-16","DOI":"10.1128\/AAC.01276-16"},{"key":"4201_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31\u201341","journal-title":"Nephron"},{"key":"4201_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/psp4.12161","volume":"6","author":"THT Nguyen","year":"2017","unstructured":"Nguyen THT, Mouksassi M-S, Holford N et al (2017) Model evaluation of continuous data pharmacometric models: metrics and graphics. CPT Pharmacometrics Syst Pharmacol 6:87\u2013109","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"4201_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2165\/00003088-199324010-00002","volume":"24","author":"D Debruyne","year":"1993","unstructured":"Debruyne D, Ryckelynck JP (1993) Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 24:10\u201327","journal-title":"Clin Pharmacokinet"},{"key":"4201_CR27","unstructured":"R Development Core Team. R: a language and environment for statistical computing. 2017. Available at: https:\/\/www.R-project.org\/"},{"key":"4201_CR28","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1365-2710.2011.01297.x","volume":"37","author":"T Aoyama","year":"2012","unstructured":"Aoyama T, Hirata K, Hirata R et al (2012) Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients. J Clin Pharm Ther 37:356\u2013363","journal-title":"J Clin Pharm Ther"},{"key":"4201_CR29","doi-asserted-by":"crossref","unstructured":"Nett J, Andes D. Fluconazole. In: Pfaller M, ed. Kucers\u2019 The use of antibiotics Sixth Edition. Vol 73. CRC Press, 2010; 1806\u20131823.","DOI":"10.1201\/b13787-151"},{"key":"4201_CR30","unstructured":"Anon. Fluconazole: dosing\/administration. Micromedex 2016. Available at: http:\/\/www.micromedexsolutions.com\/. Accessed 5 Jan 2017"},{"key":"4201_CR31","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1093\/jac\/dku124","volume":"69","author":"SJ van Hal","year":"2014","unstructured":"van Hal SJ, Chen SC-A, Sorrell TC, Ellis DH, Slavin M, Marriott DM (2014) Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre\u00ae YeastOne\u00ae for Candida albicans: a prospective observational cohort study. J Antimicrob Chemother 69:2210\u20132214","journal-title":"J Antimicrob Chemother"},{"key":"4201_CR32","volume-title":"Australian medicines handbook 2012","author":"Anon","year":"2012","unstructured":"Anon (2012) Australian medicines handbook 2012. Australian Medicines Handbook Pty Ltd, Adelaide"},{"key":"4201_CR33","unstructured":"Anon. Fluconazole vs. Candida. European Committee on Antimicrobial Susceptibility Testing; 2020. Available at: https:\/\/eucast.org\/astoffungi\/rationale_documents_for_antifungals\/. Accessed 1 June 2020"},{"key":"4201_CR34","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cmi.2015.07.005","volume":"21","author":"T Brosh-Nissimov","year":"2015","unstructured":"Brosh-Nissimov T, Ben-Ami R (2015) Differential association of fluconazole dose and dose\/MIC ratio with mortality in patients with Candida albicans and non-albicans bloodstream infection. Clin Microbiol Infect 21:1011\u20131017","journal-title":"Clin Microbiol Infect"},{"key":"4201_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-012-0018-5","volume":"52","author":"JA Roberts","year":"2013","unstructured":"Roberts JA, Pea F, Lipman J (2013) The clinical relevance of plasma protein binding changes. Clin Pharmacokinet 52:1\u20138","journal-title":"Clin Pharmacokinet"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-021-04201-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-021-04201-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-021-04201-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T09:07:06Z","timestamp":1623748026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-021-04201-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,27]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["4201"],"URL":"https:\/\/doi.org\/10.1007\/s10096-021-04201-w","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,27]]},"assertion":[{"value":"8 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Human Research Ethics Committee (LNR\/14\/SVH\/148).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Individual patient consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}